Table 7. Comparisons of pEFS of Patients... | American Society of Hematology

Table 7.

Comparisons of pEFS of Patients Between Studies NHL-BFM 90 and NHL-BFM 86

Group of Patients	Study NHL-BFM 90			Study NHL-BFM 86⁶ ^7-150			PLog Rank
Group of Patients	No. of Patients	No. of Events	% pEFS ± SE at 6 yrs	No. of Patients^7-150	No. of Events	% pEFS ± SE at 6 yrs	PLog Rank
Total	413	43 (10%)	89 ± 2	197	37 (19%)	82 ± 3	.0087

Stage I	49	1	97 ± 3	24	0	100	.43
Stage II	115	2	98 ± 1	41	1	98 ± 2	.80
Stage III	169	20 (12%)	88 ± 3	72	21 (29%)	72 ± 5	.0017
Stage III-LDH <500 U/L^7-151	77	4 (5%)	95 ± 3	35	5 (17%)	85 ± 6	.09
Stage III-LDH ≥500 U/L^7-151 abdominal	90	16 (18%)	81 ± 4	23	14 (61%)	43 ± 10	.0001
Stage IV	24	6 (25%)	73 ± 10	19	6 (32%)	67 ± 10	.58
B-ALL	56	14 (25%)	74 ± 6	41	9 (22%)	78 ± 6	.64

Group of Patients	Study NHL-BFM 90			Study NHL-BFM 86⁶ ^7-150			PLog Rank
Group of Patients	No. of Patients	No. of Events	% pEFS ± SE at 6 yrs	No. of Patients^7-150	No. of Events	% pEFS ± SE at 6 yrs	PLog Rank
Total	413	43 (10%)	89 ± 2	197	37 (19%)	82 ± 3	.0087

Stage I	49	1	97 ± 3	24	0	100	.43
Stage II	115	2	98 ± 1	41	1	98 ± 2	.80
Stage III	169	20 (12%)	88 ± 3	72	21 (29%)	72 ± 5	.0017
Stage III-LDH <500 U/L^7-151	77	4 (5%)	95 ± 3	35	5 (17%)	85 ± 6	.09
Stage III-LDH ≥500 U/L^7-151 abdominal	90	16 (18%)	81 ± 4	23	14 (61%)	43 ± 10	.0001
Stage IV	24	6 (25%)	73 ± 10	19	6 (32%)	67 ± 10	.58
B-ALL	56	14 (25%)	74 ± 6	41	9 (22%)	78 ± 6	.64

F7-150

Patients with ALCL and patients with precursor-B-cell lymphoblastic lymphoma treated in therapy group B-NHL of trial NHL-BFM 86 are not included here.

F7-151

Only patients with LDH available are considered.

View Large

This Feature Is Available To Subscribers Only